Lung · Organ at risk

Heart / Pericardium

Educational Summary

Dose constraints

Lung SBRT

ScheduleConstraintSource
30–34 Gy / 1 fx
Peripheral
Max dose <22 GyTROG SAFRON II
D15 cc <16 GyTROG SAFRON II
54 Gy / 3 fx
Peripheral
Max dose <30 GyTROG CHISEL
50 Gy / 5 fx
Central
Max dose 52.5 GyRTOG 0813
D15 cc ≤32 GyRTOG 0813

Quoted from eviQ 3389 and eviQ 4018, checked 2026-09-22. Full table with references →

Conventional / Hypofractionated Lung RT

ScheduleConstraintSource
60 Gy / 30 fx
± concurrent chemotherapy
Mean heart dose ≤20 GyWang 2017
V50 ≤25%Speirs 2017

Never at the expense of target coverage.

Quoted from eviQ 1871, checked 2026-09-22. Full table with references →

Anatomy

The heart lies in the middle mediastinum inside the pericardial sac, with its base superiorly where the great vessels enter and leave and its apex pointing anteriorly, inferiorly and to the left. Its superior boundary on CT is the part most often defined differently between atlases.

Function in the body

The heart pumps blood through the lungs and around the body.

Why it matters

  • SBRT: most relevant for tumors next to the heart or pericardium; toxicity endpoints in SBRT tables include pericarditis.
  • Conventional lung RT: cardiac dose has received growing attention in locally advanced lung cancer. Secondary analyses of RTOG 0617 are a good entry point to that literature.
  • Esophagus and upper GI: the heart sits directly in front of the lower esophagus and gastroesophageal junction, so mid and distal esophageal plans are often limited by heart dose. Liver SBRT near the dome of the liver can also bring the heart close to high dose.
  • Breast: the heart sits directly behind the left breast and chest wall, and Darby 2013 linked mean heart dose to later coronary events — which is why breast protocols ask for heart dose as low as reasonably achievable and suggest considering breath-hold techniques. Internal mammary nodal treatment can increase heart dose further. Breast protocols increasingly limit the LAD as well, because mean heart dose can stay low while the LAD receives much more.

Because the heart is a large organ, both point-dose and volume-based metrics (such as mean dose or a Vx) appear in published sources, depending on the fractionation and the endpoint.

How to contour

Feng 2011, a cardiac CT atlas built with cardiology and cardiac radiology:

  • Top: the heart starts just below the left pulmonary artery. For simplicity, a rounded contour that also takes in the great vessels can be drawn there.
  • Bottom: the heart blends with the diaphragm.
  • Include the fatty tissue inside the pericardium, because the coronary vessels run in it, even where no heart muscle is visible.
  • The superior vena cava can be contoured separately on a contrast scan; on a non-contrast scan it can be included for consistency.
  • A window level of 50 and width of 500 shows most structures.

Timmerman 2022 (Tables 8–11, written for its SBRT dose tables) contours the heart with the pericardial sac, starting at the bottom of the aortic arch (the aortopulmonary window) and ending at the heart's apex. The two sources set the top of the heart at different levels, so match the source behind your limit.

Review articleSource Verified
A Story of Hypofractionation and the Table on the Wall
Timmerman R · UT Southwestern Medical Center · 2022

An editorial history of the UT Southwestern SABR constraint tables — often called the “Timmerman tables” — covering how they were developed and revised, and their relationship to AAPM TG-101 and NRG/RTOG protocols. Tables 2–11 separate serial tissues (listed with a volume, a volume max and a max point dose) from parallel tissues (listed with a critical volume and a critical-volume dose max). In Tables 2–7 a footnote defines “point” as ≤0.035 cm³; Tables 8–11 add a contouring-instructions column for each structure.

Further reading

  • QUANTEC heart — Radiation dose–volume effects in the heart (QUANTEC) Source
  • RTOG 0813 protocol — RTOG 0813 protocol — SBRT for centrally located NSCLC Source
  • RTOG 1005 — RTOG 1005 protocol — A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer Source
  • RTOG 0617 — Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617) Source
  • Darby 2013 — Risk of ischemic heart disease in women after radiotherapy for breast cancer Source

Related concepts